Breast Cancer

Professional reference. This Breast Cancer reference is written for healthcare professionals and should be used with current local pathways, formularies and specialist advice.

Clinical overview

Breast cancer comprises biologically diverse malignant tumours arising in breast tissue. Clinical management depends on extent of disease, histological type and grade, hormone-receptor and HER2 status, patient factors and preferences. Assessment must distinguish localised, locally advanced and metastatic disease because diagnostic staging, treatment intent and follow-up differ substantially.

Presentation may follow screening or symptoms such as a new breast or axillary lump, skin or nipple change, nipple discharge or alteration in breast contour. Triple assessment—clinical assessment, imaging and tissue diagnosis—is central to symptomatic pathways. Treatment is multidisciplinary and may combine surgery, radiotherapy, endocrine treatment, chemotherapy, HER2-directed therapy and other systemic treatments according to tumour biology and stage.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Epidemiology

The burden of Breast Cancer varies by population, age, comorbidity, diagnostic definitions and healthcare setting. Prevalence figures should therefore be interpreted in the context of the source population rather than transferred uncritically to an individual patient. Case finding is most useful when linked to a clear clinical pathway and an action that changes management.

For clinicians, epidemiology is most useful as a guide to pre-test probability and service planning. It should not override atypical presentations. Differences in access to care, deprivation, multimorbidity and demographic structure can influence observed incidence, stage at diagnosis and outcomes. Local audit data may be more relevant than national averages for pathway design.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Aetiology

Most breast cancers are sporadic, arising through accumulated genetic and epigenetic changes, while a minority are associated with inherited predisposition. Risk is influenced by age, sex, reproductive and hormonal exposures, family history, previous breast pathology, prior chest irradiation, alcohol and other factors. Pathogenic variants such as BRCA1/2 and other susceptibility genes are important in selected families and can influence surveillance, surgery and systemic treatment. Risk factors alter probability but do not determine whether an individual will develop cancer.

Presentation may follow screening or symptoms such as a new breast or axillary lump, skin or nipple change, nipple discharge or alteration in breast contour. Triple assessment—clinical assessment, imaging and tissue diagnosis—is central to symptomatic pathways. Treatment is multidisciplinary and may combine surgery, radiotherapy, endocrine treatment, chemotherapy, HER2-directed therapy and other systemic treatments according to tumour biology and stage.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Pathophysiology

The pathophysiology of Breast Cancer links the initiating disease process to the clinical findings, laboratory abnormalities and complications seen in practice. Mechanisms may evolve over time and treatment can alter both the underlying process and its measurable manifestations. A mechanistic understanding is useful when deciding which abnormalities are causal, which are consequences and which may represent a second diagnosis.

No single biomarker captures the whole biological process. Results should be interpreted alongside symptoms, examination, trajectory and treatment exposure. Apparent discordance between clinical state and a laboratory value should prompt review of timing, sampling, confounding factors and alternative explanations rather than automatic escalation or de-escalation of treatment.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Clinical presentation

Presentation of Breast Cancer ranges from typical textbook patterns to incomplete or atypical syndromes. History should establish onset, tempo, severity, functional effect, previous episodes, comorbidity, medicines, recent procedures or infections, family history where relevant, and features that change urgency. Examination should be directed by the suspected diagnosis while also looking for instability and important alternative causes.

Absence of a classic feature does not reliably exclude disease. Conversely, common symptoms may have several competing explanations. The clinician should document the working diagnosis, relevant uncertainty and the findings that would trigger reassessment. In long-term disease, the patient’s own account of change from baseline is often particularly informative.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Red flags

Red flags in Breast Cancer are findings that suggest immediate physiological threat, a rapidly progressive process, a serious complication or an important alternative diagnosis. Examples vary by condition but include haemodynamic instability, severe respiratory compromise, altered consciousness, rapidly worsening organ function, uncontrolled bleeding, severe infection, new focal neurology or other evidence of acute deterioration.

Red flags should change pace as well as content of assessment. Escalation, senior review, emergency referral or admission may be needed before diagnostic certainty is achieved. Safety-netting should be explicit when outpatient management is chosen, including what deterioration looks like, who to contact and how quickly reassessment should occur.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Differential diagnosis

The differential diagnosis should explain both the presenting syndrome and important discordant findings. For Breast Cancer, consider common mimics, treatment-related effects, coexisting disease and diagnoses where delay would cause harm. The differential should narrow as objective data and response to treatment become available.

A useful differential is prioritised rather than exhaustive. Probability, severity if missed, test characteristics and the consequences of investigation all matter. Reconsider the diagnosis when the course is atypical, expected treatment response does not occur, new organ involvement appears or results cannot be reconciled with the original formulation.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Assessment

Assessment should combine immediate severity, diagnostic probability, disease extent, comorbidity, medicine exposure, patient priorities and practical ability to follow the plan. For Breast Cancer, baseline function and trajectory are often as important as a single measurement. Record relevant observations and the reasoning behind escalation or outpatient management.

Medication reconciliation is essential. Include prescribed, over-the-counter and complementary products, recent courses and adherence. Consider pregnancy potential, frailty, cognition, safeguarding, health literacy and support where these affect treatment. Shared decisions should distinguish urgent recommendations from preference-sensitive choices.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Investigations

Symptomatic breast assessment generally uses triple assessment: clinical examination, appropriate imaging and tissue sampling. Mammography and ultrasound are selected according to age and presentation; MRI has specific indications rather than routine use for every patient. Core biopsy establishes histology and enables receptor testing. Pathology should characterise invasive or in-situ disease, grade and relevant biomarkers including oestrogen receptor and HER2, with additional markers according to pathway. Staging investigations are guided by stage, symptoms and planned treatment rather than performed indiscriminately.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Management

Treatment should be agreed through a specialist multidisciplinary team. Local therapy may include breast-conserving surgery or mastectomy with appropriate axillary staging, followed by radiotherapy according to pathological and clinical risk. Systemic treatment is selected by stage and tumour biology and may include endocrine therapy, cytotoxic chemotherapy, HER2-directed treatment and other targeted agents. Neoadjuvant therapy can downstage disease and provides response information in selected subtypes.

Management also includes fertility discussion where relevant, bone health, menopausal symptoms, lymphoedema prevention and treatment, rehabilitation, psychological support and surveillance for treatment toxicity. Metastatic disease is generally managed with systemic therapy and symptom-directed local treatment, with goals balancing disease control, quality of life and toxicity.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Complications

Complications of Breast Cancer may arise from the disease itself, delayed diagnosis, organ involvement, immobility, procedures or treatment toxicity. Surveillance should focus on complications whose early recognition changes outcome. New symptoms should not automatically be attributed to the known diagnosis.

Treatment-related harm deserves the same systematic attention as disease progression. Monitoring schedules should reflect the therapy used and individual risk. Patients should know which adverse effects require urgent advice and which can be discussed at routine review. Serious adverse events should trigger review of the diagnosis, treatment intensity and future risk mitigation.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Prognosis

Prognosis in Breast Cancer is heterogeneous. It depends on disease severity and biology, comorbidity, timeliness and effectiveness of treatment, complications, adherence and social context. Population statistics can support discussion but should not be presented as an individual prediction without an appropriate validated model.

Prognostic discussion should be clinically useful: what can improve outcome, what needs monitoring, and what uncertainty remains. Functional outcome and quality of life may matter as much as conventional disease endpoints. Where disease is advanced or treatment burden is high, goals of care and supportive or palliative needs should be considered alongside disease-directed treatment.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Follow-up

Follow-up for Breast Cancer should have a purpose and a defined interval. Review symptoms, function, objective disease measures, treatment response, adverse effects, adherence and new comorbidity. The interval should shorten after treatment changes, during instability or when risk is high, and may lengthen once disease is stable.

Transitions between hospital, specialist and primary care are vulnerable points. Discharge and clinic communication should identify responsibility for tests, medicine changes, pending results and escalation. Patients should receive clear safety-netting. Periodically revisit whether the diagnosis and treatment goals remain correct rather than allowing monitoring to become a ritual.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Prevention

Prevention in Breast Cancer includes reducing modifiable risk where evidence supports benefit, preventing recurrence or progression, minimising treatment harm and improving early recognition. Advice should be proportionate and avoid implying that disease is simply the result of individual behaviour. Smoking cessation, vaccination, physical activity, nutrition and cardiovascular risk management may be relevant depending on the condition and patient.

Secondary prevention is usually most effective when embedded in routine follow-up rather than delivered as a one-off message. Review barriers to adherence, access and monitoring. Population screening or case finding should follow established recommendations; indiscriminate testing can create false positives and unnecessary treatment.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Special populations

Special populations require adaptation of the Breast Cancer pathway rather than automatic application of adult general guidance. Pregnancy and breastfeeding, childhood and adolescence, frailty, advanced age, severe renal or hepatic impairment, immunocompromise and multimorbidity can change presentation, test interpretation, treatment choice and thresholds for specialist advice.

For pregnancy, paediatrics and other populations with dedicated guidance, use the relevant specialist pathway. Frailty and limited life expectancy may alter the balance between preventive benefit and treatment burden. Communication needs, capacity and reasonable adjustments should be considered so that apparent non-adherence is not mistaken for informed refusal or vice versa.

In Breast Cancer, decisions should be revisited when the clinical trajectory changes. A useful review asks whether the working diagnosis still explains the findings, whether severity has changed, whether treatment is achieving its intended target, and whether adverse effects or a second condition now account for symptoms. Documenting this reasoning makes handover and follow-up safer and reduces automatic continuation of ineffective treatment.

For Breast Cancer, communication is part of clinical management. Explain the purpose of investigations and treatment, important uncertainty, expected response and specific reasons to seek urgent help. Where several options are reasonable, discuss benefits, burdens and monitoring requirements. Provide written information where useful and ensure responsibility for follow-up results is explicit.

Clinical practice integration

Clinical practice integration for Breast Cancer should connect diagnosis, severity, treatment and follow-up rather than treating them as separate tasks. Review the patient’s baseline, current trajectory, comorbidity, medicines and practical ability to carry out the plan. Use objective measurements when they add information, but interpret them with symptoms and examination. Escalate when deterioration is unexplained, response is poorer than expected, or the consequences of delay are substantial. Multidisciplinary input should be sought when it changes diagnosis, treatment, rehabilitation or safety. At each transition of care, specify pending tests, medicine changes, monitoring responsibility and the circumstances that require earlier reassessment. This approach supports continuity without replacing condition-specific guideline recommendations or specialist judgement.

Clinical practice integration for Breast Cancer should connect diagnosis, severity, treatment and follow-up rather than treating them as separate tasks. Review the patient’s baseline, current trajectory, comorbidity, medicines and practical ability to carry out the plan. Use objective measurements when they add information, but interpret them with symptoms and examination. Escalate when deterioration is unexplained, response is poorer than expected, or the consequences of delay are substantial. Multidisciplinary input should be sought when it changes diagnosis, treatment, rehabilitation or safety. At each transition of care, specify pending tests, medicine changes, monitoring responsibility and the circumstances that require earlier reassessment. This approach supports continuity without replacing condition-specific guideline recommendations or specialist judgement.

Clinical practice integration for Breast Cancer should connect diagnosis, severity, treatment and follow-up rather than treating them as separate tasks. Review the patient’s baseline, current trajectory, comorbidity, medicines and practical ability to carry out the plan. Use objective measurements when they add information, but interpret them with symptoms and examination. Escalate when deterioration is unexplained, response is poorer than expected, or the consequences of delay are substantial. Multidisciplinary input should be sought when it changes diagnosis, treatment, rehabilitation or safety. At each transition of care, specify pending tests, medicine changes, monitoring responsibility and the circumstances that require earlier reassessment. This approach supports continuity without replacing condition-specific guideline recommendations or specialist judgement.

Clinical practice integration for Breast Cancer should connect diagnosis, severity, treatment and follow-up rather than treating them as separate tasks. Review the patient’s baseline, current trajectory, comorbidity, medicines and practical ability to carry out the plan. Use objective measurements when they add information, but interpret them with symptoms and examination. Escalate when deterioration is unexplained, response is poorer than expected, or the consequences of delay are substantial. Multidisciplinary input should be sought when it changes diagnosis, treatment, rehabilitation or safety. At each transition of care, specify pending tests, medicine changes, monitoring responsibility and the circumstances that require earlier reassessment. This approach supports continuity without replacing condition-specific guideline recommendations or specialist judgement.

Clinical practice integration for Breast Cancer should connect diagnosis, severity, treatment and follow-up rather than treating them as separate tasks. Review the patient’s baseline, current trajectory, comorbidity, medicines and practical ability to carry out the plan. Use objective measurements when they add information, but interpret them with symptoms and examination. Escalate when deterioration is unexplained, response is poorer than expected, or the consequences of delay are substantial. Multidisciplinary input should be sought when it changes diagnosis, treatment, rehabilitation or safety. At each transition of care, specify pending tests, medicine changes, monitoring responsibility and the circumstances that require earlier reassessment. This approach supports continuity without replacing condition-specific guideline recommendations or specialist judgement.

Clinical practice integration for Breast Cancer should connect diagnosis, severity, treatment and follow-up rather than treating them as separate tasks. Review the patient’s baseline, current trajectory, comorbidity, medicines and practical ability to carry out the plan. Use objective measurements when they add information, but interpret them with symptoms and examination. Escalate when deterioration is unexplained, response is poorer than expected, or the consequences of delay are substantial. Multidisciplinary input should be sought when it changes diagnosis, treatment, rehabilitation or safety. At each transition of care, specify pending tests, medicine changes, monitoring responsibility and the circumstances that require earlier reassessment. This approach supports continuity without replacing condition-specific guideline recommendations or specialist judgement.

Clinical practice integration for Breast Cancer should connect diagnosis, severity, treatment and follow-up rather than treating them as separate tasks. Review the patient’s baseline, current trajectory, comorbidity, medicines and practical ability to carry out the plan. Use objective measurements when they add information, but interpret them with symptoms and examination. Escalate when deterioration is unexplained, response is poorer than expected, or the consequences of delay are substantial. Multidisciplinary input should be sought when it changes diagnosis, treatment, rehabilitation or safety. At each transition of care, specify pending tests, medicine changes, monitoring responsibility and the circumstances that require earlier reassessment. This approach supports continuity without replacing condition-specific guideline recommendations or specialist judgement.

Clinical practice integration for Breast Cancer should connect diagnosis, severity, treatment and follow-up rather than treating them as separate tasks. Review the patient’s baseline, current trajectory, comorbidity, medicines and practical ability to carry out the plan. Use objective measurements when they add information, but interpret them with symptoms and examination. Escalate when deterioration is unexplained, response is poorer than expected, or the consequences of delay are substantial. Multidisciplinary input should be sought when it changes diagnosis, treatment, rehabilitation or safety. At each transition of care, specify pending tests, medicine changes, monitoring responsibility and the circumstances that require earlier reassessment. This approach supports continuity without replacing condition-specific guideline recommendations or specialist judgement.

References

This reference is evidence-led and should be read alongside the authoritative guideline routes stored with this condition in MediCalc. Guidance changes over time; clinicians should confirm current recommendations, medicine licences, safety alerts and local pathways before acting. The source list includes national and international professional guidance appropriate to this topic.